After we learned that Sanofi CEO Olivier Brandicourt was barely getting by on $8.2 million last year, a lode was lifted from our shoulders when we learned that Lilly CEO Dave Ricks racked in $17.3 million last year. Now we don’t know what Lars Fruergaard Jørgensen the CEO for Novo Nordisk took down last year but our guess he’s the same ballpark as Olivier and Mr. Ricks. Not that we have anything against these guys racking in the doe but it’s easy to understand why patients and patient advocates would like to beat them . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.